VC-backed PhaseBio goes public
Pennsylvania-based PhaseBio Pharmaceuticals, a developer of treatments for orphan diseases, has raised $46 million for its IPO after pricing its 9.2 million shares at $5 per share. The stock began trading October 18, 2018 on the NASDAQ under the ticker symbol "PHAS." Citigroup, Cowen and Stifel are the lead underwriters. PhaseBio's pre-IPO backers included New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson and Fletcher Spaght Ventures.
18 October 2018•2 mins read
